Abstract:Abstract There are numerous drug development efforts of DNA damage response (DDR) targets, such as PARP, ATR, ATM, CHK1, where the ability to accurately identify responsive sub-populations for monotherapies and combinations is a major challenge. Patients are routinely assigned to these drugs based on BRCA mutation, or BRCAness profile, encompassing homologous recombination deficiencies (HRD) which do not always represent the responsive sub-populations. Since DNA replication and DNA repair mechanisms are dominated by signaling events, we hypothesized that HRD extends beyond the genomic status, and is manifested also in the level of protein expression and protein modification. To that end, we created a harmonized data atlas consisting of phenotypic drug sensitivity and basal and dynamic phosphoproteomics of multiple cell lines before and after treatment of multiple DDR drugs. Proteogenomic analysis of cell lines showed that some cell lines are sensitive to DDR drugs despite being DDR-proficient at the genomic level. Proteomic analysis of these cell lines showed that at least a third of them exhibit proteomic DDR deficiency, explaining DDR sensitivity beyond mutation status. We then utilized our proteogenomic atlas and computational platform to address challenging clinical needs, namely discovery of a predictive ATR biomarker and identifying potential combination treatments to overcome ATRi resistance. Using basal state and protein dynamics of ATR coupled with ATRi sensitivity, we developed a novel predictive ATR biomarker, and tested it using two independent validation datasets. Our ATR biomarker exhibited improved precision and recall compared to genomic biomarkers represented by mutations commonly used in the clinic, and was not confounded by mutations. In addition, integrated analysis of basal and dynamic data of multiple cell lines treated with ATRi, highlighted both known (e.g. ATM) and novel resistance mechanisms and suggested potential drug combinations. Altogether, we demonstrate here the benefit of utilizing (phospho)-proteomic data to tackle clinical challenges in DDR drug development, such as predictive biomarkers and combination strategies. We provide a proteomics-based framework that would enable future patient selection in DDR clinical trials. Citation Format: Gali Arad, Avital Hay-Koren, Nitzan Simchi, Dimitri Kovalerchik, Dina Daitchman, Amit Manor, Ofer Givton, Elyad Lezmi, Iris Alchanati, Yonatan Katzenelenbogen, Shay Herman, Alon Shtrikman, Galina Otonin, Eran Seger, Kirill Pevzner. Phospho-proteomic dynamics reveal DNA damage and repair signatures of drug sensitivity [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5130.

ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage

ATM and ATR：Sensing DNA Damage

ZNF506-dependent positive feedback loop regulates H2AX signaling after DNA damage

ATM controls the extent of DNA end resection by eliciting sequential posttranslational modifications of CtIP

Buried territories: heterochromatic response to DNA double-strand breaks.

The Activation Mechanisms of Master Kinases in the DNA Damage Response

ATM-mediated KDM2A Phosphorylation is Required for the DNA Damage Repair

A Multi-Scale Map of Protein Assemblies in the DNA Damage Response.

Regulation of DNA Damage-Induced ATM Activation by Histone Modifications

Oligomerization of MDC1 Protein Is Important for Proper DNA Damage Response

Noncanonical ATM Activation and Signaling in Response to Transcription-Blocking DNA Damage

A novel ATM-dependent pathway regulates protein phosphatase 1 in response to DNA damage.

Emerging role of protein phosphatases changes the landscape of phospho-signaling in DNA damage response.

DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation

Proteome dynamics at broken replication forks reveal a distinct ATM-directed repair response suppressing DNA double-strand break ubiquitination

FACS-based genome-wide CRISPR screens define key regulators of DNA damage signaling pathways

The Atm Kinase Induces Microrna Biogenesis in the Dna Damage Response

Abstract 5130: Phospho-proteomic dynamics reveal DNA damage and repair signatures of drug sensitivity

Beyond the Trinity of ATM, ATR, and DNA-PK: Multiple Kinases Shape the DNA Damage Response in Concert With RNA Metabolism

The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.

In-Depth Mapping of DNA-PKcs Signaling Uncovers Conserved Features of Its Kinase Specificity